Navigation Links
Regado Biosciences' REG1 Anticoagulation System Study Results Published in the Journal of Thrombosis and Haemostasis
Date:5/14/2008

in a prestigious, clinically oriented, peer-reviewed publication."

Results from Regado's 1c study were presented previously at the American Heart Association's 2007 Scientific Sessions.

About REG1 Anticoagulation System Clinical Program

In the Phase 1c clinical study, the researchers randomized 39 healthy volunteers to receive either three consecutive REG1 treatment cycles or placebo. Each REG1 cycle consisted of an intravenous (IV) bolus of RB006 dosed at 0.75 mg/kg, followed an hour later by a descending dose of RB007, ranging from a 2:1 to 0.125:1 antidote:drug ratio (1.5 mg/kg to 0.094 mg/kg of RB007). Clinical and coagulation assessments were measured for 14 days.

The Phase 1 program included two additional studies. A Phase 1a study enrolled 84 healthy volunteers, while a Phase 1b study enrolled 50 patients with stable coronary artery disease who were receiving aspirin with or without clopidogrel. The results showed an IV bolus injection of RB006 achieved, in both study populations, a prompt, consistent, and dose-dependent prolongation of activated partial thromboplastin time (aPTT). In addition, a 1 mg/kg dose of RB006 resulted in essentially complete Factor IXa inhibition. The studies also demonstrated an IV bolus injection of RB007 administered in a 2:1 antidote:drug ratio successfully reversed prolonged aPTT within a median of one minute, with no rebound increase up to seven days. Despite dual antiplatelet use in 19 subjects, there were no major bleeding or other serious adverse events observed in either study.

Based upon the combined results of the Company's Phase 1a, 1b, and 1c studies, Regado initiated REVERSAL-PCI, a multi-center, open-label, randomized Phase 2a clinical study of the REG1 anticoagulation system. The Phase 2a study is enrolling 26 patients undergoing elective percutaneous coronary intervention (PCI) to assess whether REG1 can replace standard heparin therapy during the performance of coronary balloon an
'/>"/>

SOURCE Regado Biosciences
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Neurocrine Biosciences to Present at the 2008 Citi Investment Research Global Health Care Conference
2. Kosan Biosciences to Present at the Leerink Swann Solid Tumors Roundtable Conference
3. YM BIOSCIENCES ANNOUNCES PRESENTATIONS FOR AEROLEF(TM) AT AMERICAN PAIN SOCIETY ANNUAL MEETING
4. Pressure BioSciences, Inc. to Discuss First Quarter 2008 Financial Results and Provide Business Update
5. Sangamo BioSciences Nominates Thomas G. Wiggans to Its Board of Directors
6. Sangamo BioSciences Announces First Quarter Conference Call and Webcast
7. Neurocrine Biosciences Announces Conference Call and Webcast to Present First Quarter 2008 Financial Results
8. Monogram Biosciences Announces First Quarter 2008 Financial Results Conference Call
9. Monogram Biosciences to Present at the JMP Securities Seventh Annual Research Conference
10. YM BIOSCIENCES ANNOUNCES PRESENTATIONS FOR TWO OF ITS ANTI-CANCER DRUGS AT AACR ANNUAL MEETING
11. Raven biotechnologies Announces Collaboration With Monogram Biosciences to Advance Diagnostic Cancer Technologies
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/30/2015)...   Tamir Biotechnology , a leading developer of ... Ebola antiviral therapy program. Clinical Progress ... being evaluated and considered by a number of clinicians ... the first quarter of 2015, the company participated in ... Evaluation of Potential Treatments and Vaccines For Ebola In ...
(Date:4/30/2015)... /PRNewswire/ - BioAmber Inc. (NYSE: BIOA ), an ... has commenced an underwritten public offering of its common ... a 30-day option to purchase up to an additional ... in the public offering. The offering is subject to ... to whether or when the offering may be completed, ...
(Date:4/30/2015)... ALEXANDRIA, Va. , April 30, 2015 ... provides senior debt to life sciences and healthcare services ... senior secured term loan agreement with Celula, Inc., a ... diagnosing major diseases, enabling better patient care and improved ... continue the development and expand the commercialization of its ...
(Date:4/30/2015)... April 30, 2015 Biodata, producer ... with integrated protocols and specimen management systems, and ... and consulting services for life science research, announce ... Labguru’s newest feature: chemical structure and reaction support. ... for biologists, bio-chemists, and more, the integration of ...
Breaking Biology Technology:Tamir Biotechnology Provides Update on TMR004 Development Against Mutating Ebola 2Tamir Biotechnology Provides Update on TMR004 Development Against Mutating Ebola 3Tamir Biotechnology Provides Update on TMR004 Development Against Mutating Ebola 4BioAmber Inc. Announces Public Offering Of Common Stock 2BioAmber Inc. Announces Public Offering Of Common Stock 3Oxford Finance Provides $10 Million Debt Financing to Celula 2Labguru Integrates ChemAxon's Marvin JS, to Enhance Functionality for Chemists 2
... ALEXANDRIA, Va., Dec. 9 First Coast Service Options ... in Medicare reimbursement solutions, to support a new Medicare ... Medicaid Services (CMS). , , ... disputes beginning Jan. 1, 2009 between health care providers ...
... Delcath Systems, Inc. (Nasdaq: DCTH ) today announced ... Directors. Dr. Stoll is Executive Chairman of Cortex Pharmaceuticals, Inc. ... treatment of central nervous system disorders. , ... , Prior to joining Cortex, Dr. ...
... CHESHIRE, Conn., Dec. 9 Soliris(R) (eculizumab),a terminal complement ... ), was observed by investigators to reduce blood measures,associated ... PNH. , A ... indicators of,pulmonary artery hypertension (PAH) in patients with paroxysmal ...
Cached Biology Technology:FCSO Selects Burgess as Exclusive Pricing Solution for New Medicare Contract 2Delcath Adds Senior Pharmaceutical Professional to Its Board of Directors 2Delcath Adds Senior Pharmaceutical Professional to Its Board of Directors 3Soliris(R) Reduced Measures of Thrombosis and Inflammation, and Decreased Indicators of Pulmonary Hypertension, in Studies of Patients with PNH 2Soliris(R) Reduced Measures of Thrombosis and Inflammation, and Decreased Indicators of Pulmonary Hypertension, in Studies of Patients with PNH 3Soliris(R) Reduced Measures of Thrombosis and Inflammation, and Decreased Indicators of Pulmonary Hypertension, in Studies of Patients with PNH 4Soliris(R) Reduced Measures of Thrombosis and Inflammation, and Decreased Indicators of Pulmonary Hypertension, in Studies of Patients with PNH 5Soliris(R) Reduced Measures of Thrombosis and Inflammation, and Decreased Indicators of Pulmonary Hypertension, in Studies of Patients with PNH 6Soliris(R) Reduced Measures of Thrombosis and Inflammation, and Decreased Indicators of Pulmonary Hypertension, in Studies of Patients with PNH 7Soliris(R) Reduced Measures of Thrombosis and Inflammation, and Decreased Indicators of Pulmonary Hypertension, in Studies of Patients with PNH 8
(Date:4/2/2015)... April 2, 2015 In ... by far outperforms the strongest competitors, showing outstanding ... accuracy, the system is capable of a throughput ... proves up to be ten times faster than ... runner-up performance.      (Photo: http://photos.prnewswire.com/prnh/20150402/738673-a ...
(Date:4/1/2015)... Medisafe ™, the leading global medication management platform with ... Android smartphones and tablets, announces today that ... allow patients to track and correlate their adherence directly ... be able to visualize in real-time how taking medication ... glucose levels and blood pressure. "Patients need ...
(Date:3/24/2015)... DUBLIN , Mar. 24, 2015 Research and ... addition of the "Global Iris Recognition Market 2015-2019" ... forecast the Global Iris Recognition market to grow at ... This report covers the present scenario and ... for the period 2015-2019. To calculate the market size, ...
Breaking Biology News(10 mins):DERMALOG AFIS Emerges as Performance Winner in NIST Benchmark Test 2DERMALOG AFIS Emerges as Performance Winner in NIST Benchmark Test 3Medisafe Announces Launch of Biometric Integration, Enabling Patients to Stay Adherent to Their Meds and See Tangible Health Results 2Global Iris Recognition Market 2015-2019 with 3M Cogent, Bioenable Technologies, Cross Match Technology, Iris ID Systems & Safran Dominating 2
... the impact of student research on life at American University,s ... Following a 2009 study at American University,s main dining ... dishes used when trays were removed, trays have mostly gone ... the first time, a new paper coauthored by AU professor ...
... Houston faculty members have been named Charter Fellows of ... contributions to scientific and technological innovation. UH faculty ... Paul Chu, a physics professor and chief scientist of ... Dan Luss, a professor in chemical and biomedical engineering, ...
... (H2S) may play a wide-ranging role in staving off ... print in the journal Molecular and Cellular Biology ... explores the compound,s plethora of potential anti-aging pathways. ... important endogenous signaling molecule because of its significant effects ...
Cached Biology News:Going trayless study shows student impact 2Going trayless study shows student impact 3National Academy of Inventors honors 3 University of Houston professors 2National Academy of Inventors honors 3 University of Houston professors 3Hydrogen sulfide: The next anti-aging agent? 2
... is a high-quality four-place microplate shaker with ... speed is adjustable from 100 to 1350 ... a small orbit ensure effective shaking for ... quick and easy to set for 0 ...
... Ascent FL is equipped ... luminometric measurement technologies that ... of advanced features of ... Ascent. Fluoroskan Ascent FL ...
Rabbit polyclonal to STUB1 ( Abpromise for all tested applications). entrezGeneID: 10273 SwissProtID: Q9UNE7...
... stainless steel rack holders ... mechanism that permits selection ... angles, and "snap-in" product ... rack holder will accomodate ...
Biology Products: